Hancock Whitney公司将Zimmer Biomet控股公司在2021年第1季度的股位减少了9.7%。 Hancock Whitney Corp reduced its Zimmer Biomet Holdings stock position by 9.7% in Q1 2021.
一家机构投资者Hancock Whitney公司将Zimmer Biomet控股公司在2021年Q1的股位减少了9.7%。 Zimmer Biomet报告说,最近季度的EPS价值为194美元,比协商一致的估计数超出0.07美元。 Hancock Whitney Corp, an institutional investor, reduced its Zimmer Biomet Holdings stock position by 9.7% in Q1 2021. Zimmer Biomet reported a $1.94 EPS for the latest quarter, exceeding the consensus estimate by $0.07. 该公司目前的股价为109.04美元,预计本财政年度的EPS价格为8.1美元。 The company's current share price is $109.04, with a predicted 8.1 EPS for the current fiscal year. Zimmer Biomet是整形重建产品和其他医疗技术的医疗技术公司。 Zimmer Biomet operates as a medical technology company in orthopedic reconstructive products and other medical technologies. 其他机构投资者也调整了在ZBH的股份,几个机构投资者增加了或保持了在问题1中的股份。 Other institutional investors have also adjusted their holdings in ZBH, with several increasing or maintaining their stakes in Q1.